Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05590637 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing Antipsychotic Medications in LBD Over Time

Study acronym: CAMELOT
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 9, 2025 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Aug 2025 to Aug 2026
    • Study completion date: Feb 2026 to Feb 2027
    v4
  2. Primary completion date: Oct 2024 to Aug 2025
    • Study completion date: Apr 2025 to Feb 2026
    v3
  3. Study sites: 1 to 2v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
Trial Details
NCT Number NCT05590637
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: Alzheimer's Association
Conditions
(from sponsor)		 Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Related terms Delusions, Hallucinations, Lewy Body Disease, Psychotic Disorders
Enrollment 94 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov